Expertise in
17
conditions

Dr. Boni Elewski

Dermatology
University Of Alabama At Birmingham
500 22nd St S, 
Birmingham, AL 
Expertise in
17
conditions
University Of Alabama At Birmingham
500 22nd St S, 
Birmingham, AL 

Overview

Boni Elewski is a Dermatologist in Birmingham, Alabama. Dr. Elewski is highly rated in 17 conditions, according to our data. Her top areas of expertise are Ringworm, Psoriasis, Plaque Psoriasis, and Generalized Pustular Psoriasis (GPP).

Her clinical research consists of co-authoring 168 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Dermatology

Licenses

Dermatology in AL

Hospital Affiliations

University Of Alabama Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

University of Alabama at Birmingham
500 22nd St S, Birmingham, AL 35233
Other Locations
University of Alabama Health Services Foundation PC
2000 6th Ave S, Birmingham, AL 35233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Metaderm
Study Phase: Phase 4
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Enrollment Status: Completed
Publish Date: October 29, 2021
Intervention Type: Drug
Study Phase: Phase 4
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

168 Total Publications

Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.
Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.
Journal: Journal of drugs in dermatology : JDD
Published: January 06, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Craig Elmets
Dermatology
Expertise in
18
conditions
Dr. Craig Elmets
Dermatology

University Of Alabama At Birmingham

500 22nd St S, 
Birmingham, AL 
 (0.3 miles away)
205-996-7546
Languages Spoken:
English
See accepted insurances

Craig Elmets is a Dermatologist in Birmingham, Alabama. Dr. Elmets is highly rated in 18 conditions, according to our data. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Psoriasis, Squamous Cell Skin Carcinoma, and Pityriasis Lichenoides.

Expertise in
50
conditions
Dr. Sarah Hughey
Dermatology
Expertise in
50
conditions
Dr. Sarah Hughey
Dermatology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.2 miles away)
205-801-8000
Languages Spoken:
English
See accepted insurances

Sarah Hughey is a Dermatologist in Birmingham, Alabama. Dr. Hughey is highly rated in 50 conditions, according to our data. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Melanoma, Mycosis Fungoides, and Ecthyma.

Expertise in
50
conditions
Dr. Janet Cash
Dermatology
Expertise in
50
conditions
Dr. Janet Cash
Dermatology

Office

833 Saint Vincents Dr Ste 401, 
Birmingham, AL 
 (0.8 miles away)
205-918-1475
Languages Spoken:
English
See accepted insurances

Janet Cash is a Dermatologist in Birmingham, Alabama. Dr. Cash is highly rated in 50 conditions, according to our data. Her top areas of expertise are Contact Dermatitis, Liver Spots, Universal Acquired Melanosis, and Pustules.

Frequently Asked Questions about Dr. Boni Elewski

How do I make an appointment with Dr. Boni Elewski?

You can book an appointment with Dr. Boni Elewski by calling their office at 205-996-7546. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Boni Elewski a top-rated expert for Ringworm?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Boni Elewski is classified as an Elite expert for Ringworm, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Boni Elewski specialize in?

While Dr. Boni Elewski is a Dermatology, they have specific expertise in Ringworm, Psoriasis, and Plaque Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Boni Elewski participate in research or clinical trials?

Yes. Dr. Boni Elewski has published 168 articles and abstracts on conditions like Ringworm. You can view a list of Dr. Boni Elewski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Boni Elewski accept my insurance?

Dr. Boni Elewski accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 205-996-7546 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elewski's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile